ISSN (e): 2250 – 3005 || Volume, 14 || Issue, 2|| Mar. - Apr. – 2024 ||
International Journal of Computational Engineering Research (IJCER)

# Immune Thrombocytopenia

Sanjana Mokal, Sakshi Pachkudave, Ragini Salunke, Diksha Kamble.
*Navsahyadri Institute of Pharmacy, Naigaon, Pune Tal Bhor - 412213*

***Abstract:***
*Immune thrombocytopenia (ITP) is an acquired antibody-mediated disease for which splenectomy remains a curative treatment. The diagnosis and treatment of immune thrombocytopenicpurpura(ITP)reliesprimarilyonclinical knowledgeand observationratherthan documentationofscientificallyhigh-qualityclinicaltrials.Oneofthemainobstaclestoconducting such studies and conducting a reliable meta-analysis of available data is the lack of standardized critical definitions, outcome criteria, and uniformity of terminology. Additionally, the need for comparative clinical trials has surged due to the emergence of new therapeutic agents, such as receptor agonists for thrombopoietin, and innovative therapies, like the anti-CD 20 antibody.[1]*
***Keyword:****ImmuneThrombocytopenia,Etiology,Pathophysiology,symptoms,causes, Treatment .*

---

Date of Submission: 07-04-2024 Date of acceptance: 19-04-2024

---

## I. Introduction:

Immunethrombocytopenia(ITP)isanautoimmunesyndromecharacterizedbyantibody-and cell-mediated platelet and cessation of platelet production, which can cause bleeding. The latest InternationalWorkingGroupNoterecommendsITPfordecision-makinginallcasesofimmune-mediatedthrombocytopenia,whetherornotitoccursaspartofanotherclinicallyapparentdisorder ordrugexposure(secondaryITP).withclearreceptivity.etiology(primaryITP).TheInternational Working Group also recommends a platelet count below 100 × $10^9$/l rather than 150 × $10^9$/l for diagnosis. This approach is based on the observation that less than 10% of otherwise healthy individuals with stable platelet counts between 100 and 150 × $10^9$/L develop more severe unexplained ITP within the next 10 years. This review focuses on primary ITP in adults of the population. , but covers certain aspects of secondary forms and pediatric ITP when appropriate. ManagementofITPduringpregnancyisdiscussedelsewhereinthisissue(see"Thrombocytopenia during pregnancy").

Designingprospectivecontrolledclinicaltrialshasbeenparticularlychallengingbecausepatients withchronicdiseaserepresentlessthan10%ofallpatientswithITPandhaveconsiderableclinical variability.Consequently,severalproblemsrelatedtotheoptimaltreatmentofthesepatients remained unsolved, and treatment principles were mainly based on expert opinionsHowever, ongoing randomized trials with several new pharmacological agents promise to rapidly change this scenario. The purpose of this article is to provide an updated overview of ITP in adults, focusingonourcurrentunderstandingofthemechanismsofthrombocytopeniaandnewtreatments for chronic refractory ITP.[3]




**Figure1.**

**Figure 1.** Genetic mechanisms in ITP. Breakdown of self-tolerance causes APCs (including megakaryocytes) to process platelet autoantigens and present them to autoreactive T cells, initiatingeventsthatincludestimulationofautoantibodyproductionandactivationof cytotoxicT cells. These two processes result in the destruction of peripheral platelets and the inhibition of megakaryocytesinthebonemarrow.Inaddition,plateletsneutralizedbyautoantibodiesattackby the complement cascade.[5]

ITP can be a primary condition or it can be caused by other conditions. The differential diagnosisofthrombocytopeniaandpossiblesecondarycausesofITP.Ingeneral,theincidenceof ITP varies from 2 to 4 cases100,000 person-years, with two peaks: onein the 20-20 30s years \ n slight female predominance and higher in the 60s of the same gender distribution.5,6 Although some patients experience a single episode of ITP followed by immediate remission, chronic ITP develops up to 70 years of age. % of adults with this condition. Both spontaneous and treatment- induced remission can occur several years after diagnosis.[4]

**KEY CLINICAL POINTS**

**IMMUNE THROMBOCYTOPENIA**

- Immune thrombocytopenia (ITP) is diagnosed in patients with a platelet count below 100,000 per cubic millimeter in whom other causes of thrombocytopenia have been ruled out.
- Patients with ITP who present with serious bleeding typically receive platelet transfusions, glucocorticoids, and intravenous immune globulin.
- In patients with no bleeding or nonserious bleeding, treatment decisions are guided by the patient's platelet count, age, coexisting conditions, and preference.
- Glucocorticoids are used as first-line treatment, but prolonged use should be avoided owing to adverse effects.
- For patients in whom ITP does not remit or relapses soon after glucocorticoid treatment, other medications for which there are high-quality data include thrombopoietin-receptor agonists and rituximab.
- Splenectomy is not recommended during the first year after diagnosis of ITP unless medical treatment is not available; otherwise, it is reserved for patients with ITP that is refractory to medical treatment.

ThepathophysiologyofITPiscomplexandremainsincompletelyunderstood(Figure2).The traditionalconceptisthatantibody-coatedplateletsaredestroyedprematurelyinthespleen,liver, or both due to interaction with Fcγ receptors.7Autoantibodies can also induce complement- mediated or desialylation-induced effects..destruction of platelets and inhibition of megakaryocyte function.10 However, antiplatelet\antibodies are not detected in up to 50% of patients; this raises the possibility of alternative mechanisms for platelet destruction. Abnormalities have been described in T cells, including a shift of helper T cells (Th) to type 1helper T (Th1) and type 17 helper T (Th17) phenotype , and decreased number and function. regulatory T cells,which can control the autoimmune process. Limited studies suggest that CD8 cells are also involved.[6]




**Figure2.**
**Figure2.PathophysiologicalHighlightsofSafeThrombocytopenia**.

Inspiteofthefactthatthepathophysiologyofresistantthrombocytopenia(ITP)isnotcompletely caughton,thekeyoccasionisconsideredtobetheproductionofantiplateletautoantibodies.These autoantibodies target platelets for pulverization by macrophages within the spleen, liver, or both through actuation of Fcγ receptors; this prepare is controlled by spleen tyrosine kinase (Syk). Autoantibodies may too crush platelets through other instruments and hinder platelet generation bymegakaryocytes.Antigensfromphagocytosedplateletsarethoughttobedisplayedbythemajor histocompatibilitycomplexcourseII(MHCII)to T-cellreceptors(TCRs),fortifyingautoreactive T cells. T-cell changes seen in ITP and hypothesized to be pathogenic incorporate skewing of T partner(Th)cellstowardasort1Taide(Th1)andsortn17Tpartner(Th17)phenotype,lessening ofadministrativeT-cellaction,andanincrementincytotoxicTcells.Manythinksaboutpropose thatcytotoxicTcellscanmoreoverspecificallyannihilateorrepressthegenerationofplatelets.[6]

**Immunethrombocytopenia:**

The diagnosis of idiopathic thrombocytopenic purpura (ITP), sometimes referred to as immune thrombocytopenia or immunological thrombocytopenic purpura, is made when the platelet count is less than $100 \times 10^9$/L. [10]

**Etiology:**

A platelet count of fewer than 150 x $10^9$is known as thrombocytopenia. Among neonates, especially premature ones, it is one of the most prevalent hemostatic disorders. It can result in a significant risk of bleeding and death and affects 18–35% of newborns admitted to neonatal intensive care units (NICUs). Many research showed that the degree of prematurity increases the likelihoodofincreasingthrombocytopeniaandthatimmaturenewbornshada2.52-foldhigherrisk ofthrombocytopenia.Itisgenerallydescribedasanisolatedthrombocytopenicautoimmuneillness with no known underlying etiology. There may be indications of both maternal and neonatal variables in the complicated etiology of thrombocytopenia.in the process of creating it. Thrombocytopenia typically indicates the presence of another disease, such as necrotizing enterocolitis(NEC),sepsis,orintrauterinegrowthrestriction(IUGR),howeveritmaybethesole clinicalmanifestationofanautoimmunesyndrome.Prematurenewbornswithinflammatorybowel necrosis (NEC).

A typical clinical problem that gets worse with increasing prematurity is neonatal thrombocytopenia (NT). The fundamental reasons behindNT are now starting to diverge, and a lot of formerly held beliefs have been demonstrated to have little to no supporting data. We discussed the causes of newborn thrombocytopenia. The most frequent neonatal disorders associated with NT, according to earlier research, were hypoxia, sepsis, placental insufficiency, andpreterm.Iftheinfantappearshealthy,thereasonofthrombocytopeniainanotherwisehealthy newborn is either placental insufficiency or an autoimmune or alloimmune immune response wherein the newborn's platelets are destroyed by maternal antibodies sent to it while it is still in utero.

Numerous investigations have assessed the frequency of thrombocytopenia during gestation, its cause, and the mother andresult throughout pregnancy. Pregnancy thrombocytopenia is a commonobservationthathappensaboutin7–10%offoetalcases.Thrombocytopeniagestational (GT), hypertensive conditions (preeclampsia, eclampsia, HELLP thenon-immunecausesincludevitaminB12orfolateinsufficiency,acutefattyliverofpregnancy, disseminatedintravascularcoagulation(DIC),druguse,andvitaminB12. As a whole, roughly 3-4% of pregnancies thrombocytopenia and immunological processes such asTTPandITPareassociated.Lowplateletcountsarethehallmarkofimmunethrombocytopenia (ITP), an autoimmune disease caused by autoantibodies from the mother that cross the placenta and target platelet membrane to destroy newborn platelets.[12]

**Pathophysiology:**

The etiology of secondary immune thrombocytopenia is cause-dependent and more complex thanthatofprimaryimmunethrombocytopenia.WhenapatienthasachronicHelicobacterpylori infection, their immune system produces antiplatelet autoantibodies in response to molecular mimicryofH.pyloriantigenslikeCagA.Theseantibodiescauseplateletaggregationandplatelet extrusion of p-selectin and phosphatidylserine by some strains of H. pylori, which are linked to the patient's individual HLA variation, increased monocyte phagocytic activity, and decreased FcγRIIb.Humanimmunodeficiencyvirus(HIV)andhepatitisCvirus(HCV)caninduce

autoantibodies against each other that cross-react with platelet glycoproteins to generate immunological complexes. 3 Severe[9]
Theimmunologicalresistanceofthepatient'sownplateletstoautoantigensisoneofthecritical stagesinthepathophysiologyofITP.NumerousstudiesshowthatadysregulatedT-cellresponse duringITPcausesaskewedhelperTcellbalance(Th1/Th2)ratio,whichinturncausesanincrease inthequantityandhyperactivityofcytotoxicTcells.Consequently,increasedplateletdestruction andincreasedBcellsurvivalaretheoutcomesofthisincreasedcytotoxicTcellactivity.Increased B cell survival therefore makes it easier to produce more autoantibodies, which speeds up the process of platelet elimination. Autoantibodies opsonize platelets, resulting in compromised thrombopoiesis, increased complement activation, phagocytosis, and apoptosis (Figure 3).




**Figure3.**

**Figure3:**Pathophysiologyofimmunethrombocytopenia(ITP)illustratedgraphically,showing various immune cells involved. The regulation of helper T cell-mediated B cell activation is disrupted when regulatory T cells are compromised. Autoantibodies are abundantly produced by Bcells,whichinturncauseopsonization,phagocytosis,complementactivation,desialylation,and ultimately platelet death. Megakaryocyte maturation (megakaryocytopoiesis) is further impeded by autoantibodies, and megakaryocytes and platelets are destroyed by autoreactive cytotoxic T cells.[8]

Several studies have shown new mechanisms independent of Fc-mediation, despite the fact thatconstantfragment(Fc)-dependentprocessesaccountforthemajorityofplateletdestructionin thespleen.ITP-autoantibodieshavebeendemonstratedinastudytocauseglycosylation alterationsonplateletsurfaceglycoproteins(GPs).ThisGPsalterationacceleratesplateletelimination in the liver upon additional identification by Ashwell–Morell receptors expressed on hepatocytes.Hepatocytes'platelet phagocytosis and desialylation are alsoinduced by CD8+ TlymphocytesfromITPpatients.Thiscouldelucidateapossibleexplanationfortheineffectiveness of splenectomy non certain ITP patients. A retrospective analysis of 61 ITP patients found thatplateletdesialylationledtoreducedresponsetofirst-linetherapies,regardlessofanyotherfactors. AutoantibodiesgeneratedduringITPimpactplateletsurvivalaswellas megakaryocyte-mediated formation . Research has demonstrated that autoantibodies bind to megakaryocytes and obstructtheirmaturation, whichreducestheproductionofplatelets.Invitroresearchhasshown that autoantibodies impede megakaryopoiesis and maturation, which in turn suppresses platelet formation.Nonetheless,furtherresearchisnecessarytodeterminehowmegakaryocyteapoptosis functions in thepathogenesis of ITP. Someindications and opposing statements have been found inthefindingsofpreviousandcurrentstudies.Infact,astudyshowedthattreatingmegakaryocytes withITPplasmaactuallyreducestheirapoptosis.Whenhealthyumbilicalcordbloodwasusedto separatehematopoieticstemcells(HSCs),itwascombinedwithITPpatients'plasmato create.[8]

**Symptoms:**
Theremaybenosymptomsassociatedwithimmunethrombocytopenia.Whensignsappear,they may consist of




**Figure 4.**

- Bruisingthatiseasily sustained.
- Petechiae,ortinyreddish-purplepatches,thatbleedintotheskin.Thelowerlegsarewhere the spots mostly appear. They resemble a rash.
- Bleeding into the skin greater than purpura, another name for petechiae.
- Flowingblood fromthenoseor gums.
- Hematocheziaordysuria.
- Extremelyhigh monthlyflow .

**Causes:**
In ITP, the immune system is stimulated to attack your body's own platelets. In most cases, thisisduetotheproductionofanti-plateletantibodies.Insomecases,atypeofwhiteblood cell called T cells directly attack the platelets. This immune system error can be caused by one of the following:

- Medications(includingover-the-countermedications)cancauseallergiesthatcross- react with platelets.
- Infections, usually viral infections, including the viruses that cause chicken pox, hepatitisC,andAIDS,canelicitantibodiesthatcross-react.withplatelets.reactwith platelets
- Pregnancy
- Immunesystemdisorderssuchasrheumatoidarthritisandlupus
- Low-grade lymphomas and leukemias can produce abnormal antibodies against platelets.
- Sometimesthecauseofimmunethrombocytopenicpurpurais unknown..

**Diagnosis:**
PrimaryITPisdiagnosedasanexclusioncase.Infections,medications,systemicdiseases,and primary hematologic abnormalities can all result in thrombocytopenia.10 It is important to take into account bleeding during dental work, trauma, and surgery when determining how long persistent thrombocytopenia or another bleeding disease might last. Patients can be divided into twocategoriesusingdifferentialdiagnosis.PatientswithITP,includingthosewithsystemiclupus erythematosus, areincluded in onecategory; patients with non-ITP, likethosewith leukemiaand aplastic anemia, are included in the other. Aplastic anemia can first manifest as isolated

thrombocytopenia,butanemiaandleukopeniausuallyfollowdays,weeks, months,orevenyears later. Additionally, leukemia never manifests as thrombocytopenia on its own. References to internationalconsensuspublicationsandstandardsaboutthedistinctionsbetweenprimaryITPand the other conditions should be made.

**Table 1 :Diagnosis of ITP**

| |
|---|
| 1.Thrombocytopenia(<100×$10^9$/L)intheperipheralbloodstreamwithoutmorphologicindications of dysplasia. |
| 2.Anythreeormoreof thefollowing test results,including at leastone of3,4, and 5 |
| a)Normal leukocyte count |
| b)Increasedplatelate/associateanti-GPllb/lllaantibodylevel |
| c))Ahigher proportionofreticulateplatelates |
| d)PlasmaTPOlevelthat isnormalor slightlyelevated (<300pg/mL) |
| 3.Thefollowing illnessesarenot included: |
| TP aplastic anemia , MDS, PNH, SLE, leukemia, malignant lymphoma, DIC, TTP, setsis, sarcoidosis, viral infection, and others are drug- or radiation-induced conditions .Kasabach- Merrittsyndrome,May-Hegllinabnormalities,Bernard-Souliersyndrome,andWiskott-Aldrich syndrome |

**Abbreviations:** GP stands for glycoprotein; TPO stands for thrombopoietin; TP stands for thrombocytopenia; MDS stands for myelodisplastic syndrome; PNH stands for paroxysmal nocturnal hemoglobinemia; SLE stands for systemic lupus erythematosus; DIC stands for disseminated intravascular coagulation; and TTP stands for thrombotic thrombocytopenia.[11]

**Table2:Adjudication criteriaforthediagnosisofthrombocytopenia:**

| Diagnosis | Adjudication criteria |
|---|---|
| Mild thrombocytopenia | ● A reliable platelet count falls between 100and150×$10^9$/L.Takeintoaccount gestational thrombocytopenia if a patient is expecting. Mild thrombocytopenia takes precedence overotherdiagnoses (suchHepatitisC or a family history of thrombocytopenia). |
| PrimaryITP | ● In patients with platelets <100 × 10^9/Lwithotherdiagnoses,theinitial ITP diagnosis should be maintained if the platelet count increases to >100. |

| | |
|---|---|
| SecondaryITP<br>● HepatatisC<br>● HIV<br>● Non-specificinfection<br>● Pregnancyassociated ITP<br>● Lymphoma<br>● Sarcoidosis<br>● Otherautoimmune disease | ● Even if the underlying illness is cured and the ITP persists, the diagnosis of secondary ITP should stand.<br>● ThediagnosisofprimaryITPshouldbe made if the ITP persists postpartum or precedes pregnancy, in which case the accompanying ITP platelets should improve with ITP treatment. |
| Drug-inducedITP | ● Withnoadditionalmedicinesinvolved, thrombocytopeniausuallydevelops5– 10 days after the first drug exposure and platelet count recovery usually happens after stopping the drug. To verify the information, either a drug test or the evidence of drug-induced antibodies in the platelets |
| Non-immune thrombocytopenia<br>● Alcoholrelated<br>● Incidental thrombocytopenia in pregnancy (gestational thrombocytopenia)<br>● Hypertensivedisordersofpregnancy<br>● Liverdisease<br>● Drug-induced bone marrow suppression<br>● Thrombocytopenia associated with malignancy including aplastic anemia | ● The platelet count is normally higher than 70 $10^9$/L during pregnancy for incidental thrombocytopenia of pregnancy (gestational thrombocytopenia), and normalization of platelet count postdelivery, no history of thrombocytopenia (apart from during a previous pregnancy), and no thrombocytopeniainthefetusorinfant.<br>● Non-immune thrombocytopenia is usually not caused by fatty liver disease alone (without additional stigmasofchronicliverdisease). |
| Otherthrombocytopenia disorders<br>• Cyclicalthrombocytopenia<br>• Heparin-inducedthrombocytopenia<br>• Thromboticmicroangiopathies | ● Independent of therapy, there should be evidence of significant changes in plateletcountsincasesofcyclical thrombocytopenia.Ifvariations |

| | |
|---|---|
| | disappear but the platelet count remainslow,ITPshouldbesuspected. |

The method of making a clinical diagnosis of thrombocytopenic diseases is dependent on the provider and the region, is not standardized, and is subject to ascertainment bias. We created a diagnosis procedure that is more accurate for patients with thrombocytopenic diseases.Patients whose diagnosis changed from one visit to the next, those who experienced thrombocytopenia during pregnancy (due to overlap with other reasons), and those in which the origin of the thrombocytopenia remained unknown were all subject to the adjudication criteria .Hierarchical guidelines were used as adjudication criteria to determine when a patient should be classified as primary,secondary,ornon-ITP,orwhenthediagnosiswasdeemed"unknown"duetouncertainty. According to our findings, 70.7% of patients who matched the criteria for adjudication had a change in diagnosis.
Adjudication standards (92/130), and that the five most frequent modifications were from unknowntoprimaryITP(n=15);fromprimaryITPtosecondaryITP(n=10);andfromunknown to non-ITP.(n¼10); distinct reason for non-ITP (n¼10); and key ITP for non-ITP (n¼9).The employmentofanindependentadjudicator,therangeofthrombocytopenicillnessesincluded,and theapplication ofasystematicapproach to theidentification ofthrombocytopenicdisorderswere thestudy'sstrengths.Thelengthyprocess'sdrawbackswereetherequirementforfurtherprospective validationstudiesandthepossibilitythatitwouldbechallengingtoimplementinabusive clinical settings. [2]

**Treatment:**
**First-linetreatment:**

Corticosteroids are the main treatment for ITP in adults. It has been demonstrated that dexamethasone and prednisone alter B-cell and dendritic cell activation, which reduces the immune system's ability to destroy platelets . Steroids can help up to 80% of patients, however many of them relapse after taking them.are progressively smaller. The cornerstone of treatment foralongtimewasprednisone,usuallyadministeredatadoseof1mg/kg/dforaperiodoftwoto four weeks. However, new research indicates that high-dose dexamethasone ismuch more efficacious. A Hong Kong trial including 125 patients whose baseline platelet counts were less than 20 x$10^9$/L showed that in 50% of responders, a

single, brief course of dexamethasone (40 mg daily for four days) resulted in a stable platelet count higher than $50 \times 10^9$/L.
ForITPpatientswhoarepregnantandrequiretreatment,corticosteroidsarethoughttobesafe
. It's evident that high-dose dexamethasone, or corticosteroids in general, work well as an initial treatmentforITP.Thecorticosteroidadverseeffectprofile,whichincludesdiabetes,hypertension, and weight gain, can be anissue for certain patients, but corticosteroids are still a first-line medicationthatissuitableandtypicallysafetouse.Intravenousimmunoglobulin(IVIG)or

$Rh_o$(D) immune globulin (anti-RhD) can be added to treat steroid-resistant patients in order to improve the outcome. Furthermore, in cases when corticosteroids are prohibited, patients may benefitfromthesetwotreatments.Additionally,IVIGisrecommendedwhenplateletcountsmust beelevatedquickly,asinsituationsinvolvingsevereandongoingbleeding,andincertainpatients, itmaybeusedincombinationwithcorticosteroids.Theusualdosageisaninfusionof1g/kg/day foradurationofonetotwodays;however,thedoctor'spreferencemayinfluencetheregimen.In atrialof19individualswithchronicITP,IVIGhada75%responserate,stoppingactivebleeding within 12 hours of the onset of bleeding and increasing platelet counts.
Intravenous immunoglobulin (IVIG)or $Rh_o$(D)immuneglobulin (anti-RhD)can be added to treat steroid-resistant patients in order to improve the outcome. Patients who cannot receive corticosteroidscan alsoreceivethesetwotherapies.Whenplateletlevels must bechecked, IVIG is also indicated.elevated quickly, for example in situations involving severe and ongoing bleeding, and in some patients, it may be used in combination with corticosteroids. According to thephysician'sdesire,regimenscandifferfromthestandardone-totwo-dayinfusionof1g/kg/day
. Research conducted on 19 individuals suffering from chronic ITP revealed that 75% of them responded to IVIG, resulting in a stoppage of bleeding within 12 hours of the onset of bleeding and an elevation of platelets.[13]

**Secondline treatment:**

Thus, the choices for second-line treatment of adults with ITP are the main topic of discussion here. Since many individuals will not be able to take corticosteroids to produce a long-lasting remissionandmayexperiencesevereandsymptomaticthrombocytopenia;mostpatientswillneed second-line therapy since the long-term adverse effects of corticosteroids are intolerable . There are significant differences between the three main possibilities. Table II outlines the benefits and dangers associated with each of the three options: rituximab, splenectomy, and TPO-receptor agonists. First, there is a difference between therapies that alter the course of the disease (splenectomy, rituximab) in the hopes of achieving a long-lasting, total remission, and therapies that only offer symptomatic relief by keeping platelet counts elevated as long as the therapy is continued.

**Splenectomy.**

Therefore, the primary focus of this discussion is on options for adults with ITP's second-line treatment. Given that many people won't be able to use corticosteroids to achieve a permanent remission and may develop severe and symptomatic thrombocytopenia; the majority of patients willrequiresecond-linetherapysincecorticosteroidshaveunbearablelong-termsideeffectsThe three primary options differ greatly from one another. The advantages and risks of the three options—rituximab, splenectomy, and TPO-receptor agonists—are listed in Table II. First, there isadistinctionbetweentreatmentsthataimtoachieveacompleteandlong-lastingremissionby changing the course of the disease (rituximab, splenectomy) and those that merely provide symptomatic relief by maintaining elevated platelet counts as long as concluded that the data did not offer enough proof to back up the choice of whether to perform or postpone a splenectomy . Surgical problems are becoming less frequent with thepractice laparoscopic surgery, but they're stillimportant.In29casesoflaparoscopicsplenectomyforITP,thesurgery-relatedmortalitywas 0.2% (3 of 1301 patients); complications necessitating further care happened in 9.6% of patients [3].

**Rituximab**

There are fewer statistics available for rituximab side effects and the likelihood of lasting remissions than there are for splenectomy. A comprehensive analysis found that 63% (95% CI, 53–73%)ofpatientshadanoverallresponse(plateletcountgreaterthan50,000/lL)and44%(95% CI,30–58%)ofpatientshadafullplateletcountresponse(plateletcountmorethan150,000/lL)[. Just 10.5 months were the median response time . Response rates of 31%and 33% ]have been recordedinothertrials.Theinformationaboutthedangersassociatedwithrituximabtreatmentfor ITP patients is inconclusive. According to the systematic evaluation, 9 (2.9%) of the 306 individuals had died and 10 (3.7%)

experienced serious or potentially fatal toxicities.[14]

**TreatmentforpatientswithchronicrefractoryITP:**

Since there is little prospect of bringing about a long-lasting remission in patients with chronic refractory ITP, achieving enough stable platelevels, while reducing unfavorable incidents. Generally speaking, corticosteroids are used in combination with other medications to treat individuals with refractory ITP.Selecting the best course of action for chronic refractory ITP presents a number of issues for clinicians. Even if a number of choices are employed in practice, the majority of the current therapy recommendations are not supported by evidence because they arebasedonexpertopinionanduncontrolledcohortstudies.Theinconsistencyinthecriteriaused to define platelet count outcomes among research poses a challenge to the assessment and comparison of published trials. Additionally, key clinical outcomes like bleeding and quality of lifearenot consistentlymeasured.With these agents, responses rarely go over 30–35%, and with certain agents, such azathioprine, a response could not show up for several weeks.

**Newtreatmentapproaches:**

ThrombopoieticgrowthfactorsсuchasRomiplostimandEltrombopag,targetthethrombopoietin (TPO)receptorandoffer auniquetherapeutic approachforthetreatmentofITP.Romiplostimis anFc-peptidefusionprotein,whileeltrombopagisatiny,orallyadministeredhydrazonechemical molecule. Both medications stimulate megakaryocyte development and maturation, which raises plateletproduction.TheyareagonistsfortheTPOreceptor.TheoutcomeoftheThefirstphaseIII trials in individuals with and without splenectomies have been published. They are randomized, controlled,andissuedforromiplostim.Inbothsplenectomizedandnon-splenectomizedpatients, romiplostim elevated and maintained platelet levels; 83% of patients treated with romiplostim experienced an overall platelet response, compared with 7% of patients receiving a placebo (P < 0.0001; Cochran-Mantel-Haenszel test); Adrian Newland's article provides a more detailed descriptionoftheseresults.Forthetreatmentofpeoplewithpersistent ITP,romiplostimhasnow receivedapprovalintheUSAandAustralia.Publishedarethefirstphase IIItrialsinvolvingboth splenectomized and non-splenectomized people.

They are managed, randomized, and romiplostim , a release. Romiplostim increased and maintained platelet levels in both splenectomized and non-splenectomized patients; 83% of patientstreatedwithromiplostimhadanoverallplateletresponse,comparedwith7%ofpatients receiving a placebo (P < 0.0001; Cochran-Mantel-Haenszel test); Adrian Newland's article goes into further detail about these findings. Romiplostim is currently approved in the USA and Australia for the treatment of individuals with chronic ITP.[15]

## II. Conclusion:

In conclusion, the existence of active bleeding, the patient's age, the platelet count, and their lifestyle all play a role in the decision of whether or not to treat an ITP patient.concerning the likelihood of bleeding, the existence of extra risk factors for bleeding, possible side effects from theavailabletreatment,andthepatient'spersonal preferences. Instable, asymptomaticpatients,a vigilant observation strategy may be preferable to therapy because current treatment choices involve side effects that can be even more harmful than the disease itself. Although there are guidelinesfortreatingindividualswithITP,theyarestillprimarilybasedonTherearеestablished guidelines for the treatment of patients with ITP, but they still primarily rely on expert clinical judgment rather than empirical facts due to a dearth of data from studies and randomized, controlled trials. We require additional information from carefully planned, randomized, controlled trials looking into novel medications in the treatmentof individuals with ITP. Based onthephaseIIIfindings,romiplostimappearsto beapromisingtreatmentchoiceforpeoplewith this chronic illness due to its good efficacy and tolerability. [15]

## Referance:


[1]. Adeline Furdol, MD, Etienne Riviere, MD, PhD, Adult primary immune thrombocytoenia,spleenhistologyfindingandoutcomesaccordingtorituximab use based on analysis of 41 cases, Page no.1 to 2

[2]. Francesco Rodeghiero, Roberto Stasi, Blood journal, Standardization of terminologydefinitionandoutcomescriteriainimmunethrombocytopenicpurpura (ITP)ofadultsandchildren:reportfromaninternationalworkinggroup2008,Page no.3 to 5

[3]. Adam Cuker, Douglas B. Cines, Immune thrombocytopenia, Department of medicine of pathology and laboratory medicine university of Pennsylvania,Philadelphia PA ,Page no.5 to 6

[4]. Roberto Stasi, Maria Laura Evangelista, Idiopathic thrombocytopenic purpura: current concept in pathophysiology and management 2008 Page no.245 to 256

[5]. DrewProven,JohnWSemple,Recentadvanceinthemechanismandtreatment of immune thrombocytopenia.Page no. 4 to 6

[6]. NicholaCooperMDMBBS,WaleedGhanimaMBCh.BPh.D,Immune thrombocytopenia pg no. 945 to 946

[7]. OlssonB,AndersonPO,T-cellmediatedcytotoxictowardsplateletsin chronic idiopathic thrombocytopenic purpura Nat med 2003

[8]. Anurag Singh, Primary immune thrombocytopenia novel insights into

pathophysiogyanddiseasemanagement,Journalofclinicalmedicine,Pageno.2to 3
[9]. Mihnea-AlexanduCaman, Pathophsiology diagnosis and treatment of immune thrombocytopenia, International journal of medical student, Page no.1 to 2
[10]. SiyuSun,RolfT.Urbanus,Plateletsactivationmechanismandconsequences of immune thrombocytopenia, cells, Page no. 4
[11]. ShosakuNomura,Advanceindiagnosisandtreatmentfor immune thrombocytopenia, Page no. 17-18
[12]. Mohamad HoseinLookzadeh, Immune and Non-immune etiology of thrombocytopenianeonatal and maternal causes, World journal of peri and neonatology, Page no. 79
[13]. Margot samson, Treatment for primary immune thrombocytopenis : A review, Emergency medicine university of central florida college of medicine, page no.2 to 7
[14]. JamesN.George,Sequenceoftreatmentforadultwithprimaryimmune thrombocytopenia, page no. 12 to 13
[15]. Roberto Stasi, immune thrombocytopenia purpura : the treatment paradigm, Department of medical sciences, page no. 13 to 17